Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Biogen Inc.
DescriptionAntibody targeting C-type lectin domain family 4 member C (CLEC4C; BDCA2)
Molecular Target C-type lectin domain family 4 member C (CLEC4C) (BDCA2)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationLupus
Indication DetailsTreat systemic lupus erythematosus (SLE)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today